The multidistrict litigation (MDL) involving SSRI antidepressant birth defect claims against pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer has resumed activity after a period of judicial pause. Families who allege that medications like Paxil (paroxetine) and Zoloft (sertraline) caused serious congenital defects when taken during pregnancy are once again seeing their cases move through the federal court system. For parents who have been waiting — in some instances for years — this resumption signals a critical phase in one of the longer-running pharmaceutical injury litigations in the United States. The SSRI birth defect MDL has a complicated procedural history. Cases were consolidated in the U.S.
District Court for the Eastern District of Pennsylvania under Judge Cynthia Rufe, and at various points the litigation has experienced stays, bellwether trial selections, and settlement negotiations that have slowed individual case resolution. The recent resumption means that discovery, depositions, and trial scheduling are expected to pick back up, giving plaintiffs renewed opportunity to pursue compensation. A specific example illustrates the stakes: a mother in Texas who took Paxil during her first trimester later gave birth to an infant with a serious atrial septal defect requiring open-heart surgery. Her case, originally filed in state court, was transferred into the federal MDL years ago and sat largely dormant during the litigation pause. With proceedings resuming, her claim — and hundreds like it — may finally approach resolution.
Table of Contents
- Why Have the SSRI Birth Defect Cases Against GSK and Pfizer Resumed After a Pause?
- Which Birth Defects Have Been Linked to SSRI Use During Pregnancy?
- How the Cases Against GSK Differ From the Cases Against Pfizer
- What Families Should Know About Filing or Maintaining a Claim
- Challenges and Limitations Plaintiffs May Face Going Forward
- The Role of FDA Warnings and Regulatory History in These Cases
- What the Resumption Means for the Future of SSRI Birth Defect Litigation
- Frequently Asked Questions
Why Have the SSRI Birth Defect Cases Against GSK and Pfizer Resumed After a Pause?
The pause in litigation was not unusual for a complex pharmaceutical MDL. Courts sometimes issue stays to allow for global settlement discussions, to wait for scientific evidence to mature, or to manage an overwhelming volume of individual claims. In this case, the litigation pause appeared to stem from a combination of factors: ongoing negotiations between plaintiffs’ steering committees and defendants, judicial resource constraints, and the need to organize remaining claims after earlier waves of settlements and dismissals. As of recent reports, the court has lifted the stay and set new scheduling orders for active cases. GSK faced the earliest and heaviest wave of litigation, largely because Paxil was the first SSRI to receive an FDA warning — back in 2005 — about the risk of cardiac malformations in infants exposed during the first trimester.
The FDA eventually changed Paxil’s pregnancy category from C to D, a significant regulatory signal that the drug posed demonstrated fetal risk. Pfizer’s Zoloft litigation built more slowly, with plaintiffs arguing that the company knew or should have known about birth defect risks and failed to adequately warn prescribing physicians and patients. The resumption matters for practical reasons. Statutes of limitation and repose can threaten claims that sit idle for too long, and some plaintiffs’ attorneys have expressed concern that further delays could jeopardize cases procedurally. By reactivating the docket, the court is effectively putting both sides on notice that the remaining claims need to move toward trial or resolution. However, it is worth noting that a resumption of activity does not guarantee quick outcomes — pharmaceutical MDLs can remain active for years after a pause is lifted.
Which Birth Defects Have Been Linked to SSRI Use During Pregnancy?
The birth defects alleged in the mdl span a range of congenital malformations, but cardiac defects have historically been the most prominent. These include atrial septal defects (holes between the upper chambers of the heart), ventricular septal defects, and persistent pulmonary hypertension of the newborn (PPHN), a serious condition where the infant’s circulatory system fails to transition normally after birth. Other alleged defects include craniosynostosis (premature fusion of skull bones), omphalocele (abdominal wall defects), and club foot. The scientific literature on SSRIs and birth defects is genuinely mixed, which is one reason this litigation has been so protracted. Some large epidemiological studies have found a modest but statistically significant increase in cardiac malformations associated with first-trimester SSRI exposure, while other studies have found no significant association after controlling for the underlying maternal depression.
This scientific uncertainty cuts both ways in court: defendants argue that the evidence does not establish causation, while plaintiffs point to the studies showing elevated risk and to internal company documents suggesting the manufacturers were aware of warning signals earlier than they disclosed. However, if a child was born with a defect and the mother took an SSRI during pregnancy, that alone does not establish a viable legal claim. Plaintiffs must typically show that the specific SSRI was a substantial contributing factor to the specific defect, which requires expert medical testimony. Cases involving cardiac defects and Paxil have generally been considered the strongest, given the FDA’s category D warning. Claims involving other SSRIs or non-cardiac defects face a higher evidentiary burden and have historically been more difficult to litigate successfully.
How the Cases Against GSK Differ From the Cases Against Pfizer
The litigation against GSK (primarily over Paxil) and the litigation against Pfizer (primarily over Zoloft) have followed distinct legal trajectories despite being part of related MDL proceedings. GSK’s Paxil litigation is more mature. GSK has already gone through several bellwether trials and has reportedly resolved a significant number of individual claims through confidential settlements over the years. The key evidence against GSK includes internal study data — particularly a study known as Study 349 — that plaintiffs allege showed the company was aware of birth defect signals and downplayed them in communications with regulators and physicians. Pfizer’s Zoloft litigation has been more contentious on the issue of general causation — whether Zoloft can cause birth defects at all.
In earlier phases of the MDL, some Zoloft bellwether cases were dismissed or resulted in defense verdicts, with courts finding that plaintiffs’ expert testimony on causation did not meet the Daubert standard for scientific reliability. This was a significant setback for the Zoloft plaintiffs’ bar, though it did not end the litigation entirely. Some claims survived, and the question of whether improved or additional expert testimony can satisfy the causation threshold is likely to be revisited as the cases resume. For families trying to understand where their claim fits, the distinction matters. A Paxil cardiac defect claim generally has a more developed evidentiary foundation and a more favorable litigation history than a Zoloft claim involving a non-cardiac defect. That said, every case depends on its specific facts, and the strength of a claim turns on the particular medication, the timing of exposure, the type of birth defect, and the quality of the medical records linking the two.
What Families Should Know About Filing or Maintaining a Claim
If you believe your child’s birth defect may be related to SSRI use during pregnancy, the most important step is to consult with an attorney who has specific experience in pharmaceutical birth defect litigation — and to do so promptly. Statutes of limitation vary by state and by the type of claim, and the clock may have started running from the date of birth, the date the defect was diagnosed, or the date you learned (or should have learned) about the potential connection to the medication. Missing a filing deadline can permanently bar an otherwise valid claim. For families who already have cases filed in the MDL, the resumption of activity means you should expect to hear from your attorney about next steps. This may include updated medical record requests, deposition scheduling, or potential settlement discussions.
If you have not heard from your attorney in some time, it is worth reaching out proactively — litigation pauses sometimes lead to communication gaps between counsel and clients, and you have every right to know the status of your case. There is a tradeoff between joining an MDL and filing in state court. MDLs offer efficiency and shared resources among plaintiffs, but individual cases can get lost in the volume, and the pace is dictated by the court and the plaintiffs’ steering committee rather than by any single family. Some plaintiffs’ attorneys have pursued state court filings in jurisdictions perceived as more favorable, though defendants often seek to remove these cases to federal court and consolidate them in the MDL. Discussing the strategic considerations with your attorney is essential, as the right approach depends on your state, your specific facts, and the current procedural posture of the litigation.
Challenges and Limitations Plaintiffs May Face Going Forward
One of the most significant challenges in SSRI birth defect litigation is the causation question. Even with the litigation resuming, defendants will continue to argue that SSRIs have not been conclusively proven to cause birth defects and that confounding factors — including the underlying maternal depression itself, which has its own associations with adverse pregnancy outcomes — explain any observed statistical correlations. Plaintiffs who cannot present strong expert testimony linking their specific SSRI to their child’s specific defect will struggle to survive summary judgment motions. Another limitation involves the passage of time. Many of the children at the center of these claims were born in the mid-2000s to early 2010s, meaning they are now teenagers or young adults.
While the severity of their conditions has not diminished, the logistical challenges of locating and organizing medical records, securing treating physician testimony, and calculating damages over a longer time horizon can complicate case preparation. Witnesses’ memories fade, medical providers retire or relocate, and the documentary record becomes harder to assemble. Families should also be aware that even if the MDL results in favorable bellwether verdicts or global settlement discussions, the timeline for receiving any compensation can be lengthy. Pharmaceutical companies routinely appeal adverse verdicts, and settlement distribution in an MDL involves a claims administration process that can take months or years after an agreement is reached. Managing expectations about timing is important — the resumption of litigation is a positive development, but it is the beginning of a new phase, not the end of the process.
The Role of FDA Warnings and Regulatory History in These Cases
The FDA’s regulatory actions have played an outsized role in shaping this litigation. When the FDA changed Paxil’s pregnancy category to D in 2005 and issued a public health advisory about PPHN risks associated with SSRI use after the twentieth week of pregnancy, it provided plaintiffs with powerful evidence that federal regulators recognized a safety signal. Plaintiffs’ attorneys have used these regulatory actions to argue that the manufacturers either knew about the risks before the FDA acted or were negligent in not conducting adequate studies earlier.
For example, GSK’s own internal documents — some of which were unsealed during the litigation — reportedly showed that the company had access to pregnancy registry data and animal study results that raised red flags about Paxil and cardiac defects prior to the FDA’s reclassification. Plaintiffs argue this evidence supports claims of failure to warn and, in some cases, fraud. Defendants counter that they complied with all FDA requirements and that the regulatory framework, not individual manufacturers, determines what warnings are appropriate and when.
What the Resumption Means for the Future of SSRI Birth Defect Litigation
The reactivation of these cases comes at a time when pharmaceutical litigation more broadly is under scrutiny, with courts and legislatures debating the efficiency of the MDL system and whether it adequately serves plaintiffs. The SSRI birth defect MDL is in some ways a case study in the challenges of mass tort litigation: scientific uncertainty, procedural complexity, and the tension between achieving global resolution and ensuring that individual families receive fair treatment. Looking ahead, several developments could shape the trajectory of these cases.
New epidemiological research could strengthen or weaken the causation arguments. Bellwether trial outcomes — if cases proceed to trial — will signal how juries respond to the evidence in its current state. And the willingness of GSK and Pfizer to engage in meaningful settlement negotiations will depend in part on their assessment of litigation risk as cases move forward. For affected families, the most important thing is to stay engaged with their legal counsel, ensure their cases are properly maintained, and understand that while the process is slow, the resumption of activity represents genuine forward movement.
Frequently Asked Questions
Which SSRIs are involved in the birth defect MDL?
The primary medications at issue are Paxil (paroxetine), manufactured by GSK, and Zoloft (sertraline), manufactured by Pfizer. Other SSRIs such as Prozac (fluoxetine), Lexapro (escitalopram), and Celexa (citalopram) have also been the subject of individual lawsuits, though the consolidated MDL has focused most heavily on Paxil and Zoloft.
What types of birth defects qualify for a claim?
Cardiac defects — particularly atrial and ventricular septal defects — have the strongest evidentiary support in the litigation, especially in connection with Paxil. Other defects alleged in claims include persistent pulmonary hypertension of the newborn (PPHN), craniosynostosis, omphalocele, and club foot. The viability of a claim depends on the specific defect, the medication, and the timing of exposure during pregnancy.
Is there a deadline to file a claim?
Yes. Statutes of limitation vary by state and can range from one to several years from the date of injury, diagnosis, or discovery of the potential link to the medication. Because these deadlines are strict and fact-specific, consulting with an attorney as soon as possible is critical. The litigation pause did not necessarily toll (extend) individual filing deadlines.
Has there been a global settlement in the SSRI birth defect MDL?
As of the most recent available information, there has been no publicly announced global settlement resolving all claims. GSK has reportedly settled individual Paxil cases over the years, but the terms of those settlements are typically confidential. Pfizer’s Zoloft cases have had a more difficult litigation path and fewer reported resolutions. The resumption of the MDL could prompt renewed settlement discussions.
Do I need to prove that the SSRI definitely caused my child’s birth defect?
In civil litigation, the standard is generally “more likely than not” — meaning you must show that it is more probable than not that the SSRI was a substantial contributing factor to the birth defect. This is lower than the “beyond a reasonable doubt” standard in criminal cases, but it still requires credible expert medical testimony and supporting evidence. Simply having taken an SSRI during pregnancy is not sufficient on its own.
Can I file a claim if I took a generic version of Paxil or Zoloft?
This is a detailed legal question. Under federal law, generic manufacturers are generally required to use the same labeling as the brand-name drug, and the Supreme Court’s decision in PLIVA v. Mensing has made it difficult to sue generic manufacturers for failure to warn. However, claims may still be viable against the brand-name manufacturer in some circumstances, and state laws vary. An attorney experienced in pharmaceutical litigation can evaluate whether a claim is viable based on the specific facts.
You Might Also Like
- Roundup Cancer MDL — 50,000 Claims Remain After Bayer’s $10.9B Settlement Attempts
- 3M Combat Earplug MDL — $6.01B Settlement Final After Largest Mass Tort Payout in History
- Suboxone Tooth Decay MDL — Indivior Faces Dental Damage Claims in Ohio Federal Court